ACCESSWIRE
19 Jan 2023, 19:05 GMT+10
The biotechnology company has established a promising in-vivo platform for the development of its lead therapy, a monoclonal antibody that stops blistering in chronic skin conditions without suppressing the immune system.
MILAN, ITALY / ACCESSWIRE / January 19, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin blistering diseases, has announced the generation of a transgenic mouse model that will provide an effective in-vivo platform for the development of its lead candidate. This innovative therapy is a fully human anti-FasL monoclonal antibody that stops blistering, without suppressing the immune system, thus avoiding side effects typical of immune-suppressant treatments.
In two independent studies, PinCell's lead candidate has shown the reduction or the prevention of the formation of blisters in ex-vivo human models of pemphigus. The new mouse model will allow the production of in-vivo proof of concept data and the development of a solid understanding of how the antibody's blockade of excess human soluble Fas ligand relates to the effective treatment of pemphigus.
The company's newly appointed Chief Executive Officer, Dr. Antonino (Tony) Amato, said PinCell's transgenic mouse model will provide 'the icing on the cake' on what has been proven so far. 'The mouse genome was modified so that mice would produce the human FasL protein, allowing the use of our human antibody against it, by selectively recognizing the human form of such a protein. The humanized FasL mouse model is a valuable tool to study the involvement of the Fas/FasL pathway also in other diseases in which this pathway may play a key role in disease development and progression.'
Pemphigus is a rare condition that affects about 330,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream to the immune system, at the level of skin cells, this new mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants.
Luigi Costa, Chairman of PinCell's Board of Directors, commented: 'We are pleased to welcome Tony during this important time in the company's development. He brings to PinCell a very relevant expertise in drug development and the leadership needed to guide the company to accelerate the development of our lead therapeutic candidate.'
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
Contact:
Tony Amato
CEO, PinCell
a.amato@pincell.com
+39-334-6263471
SOURCE: PinCell
Get a daily dose of Illinois Intelligencer news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Illinois Intelligencer.
More Information(Photo credit: Nick Turchiaro-USA TODAY Sports) The Nashville Predators will look to avoid consecutive losses when they visit the Montreal ...
Gaza's Hamas-run health ministry says Israel's pounding of Gaza has killed close to 18,000 people, most of them women and ...
Nashville (Tennessee) [US], December 10 (ANI): Six people died after tornadoes and strong thunderstorms hit Tennessee, US, according to CNN. ...
The U.S. State Department has approved the emergency sale of 14,000 rounds of tank ammunition to Israel for about $106.5 ...
Washington, DC [US], December 10 (ANI): Researchers have found a tyrannosaur's last meal perfectly preserved inside its stomach cavity, as ...
chicago, illinois - The U.S. Soccer Federation and Mexico Football Federation submitted a joint bid Friday to host the 2027 ...
WASHINGTON, DC - Within hours of blocking a UN Security Council resolution from demanding a ceasefire in the current Mideast ...
WASHINGTON D.C.: In a sign of the challenges ahead for his 2024 re-election bid, a new Reuters/Ipsos poll showed that ...
Israel has acknowledged and thanked the United States and President Joe Biden for standing firmly by Israel's side at the ...
NEW YORK: This week, New York City officials said that one person was killed and six others were injured when ...
NEW YORK, New York - The United Kingdom refrained from supporting demands for a ceasefire in the two-months long Israel-Gaza ...
NEW YORK, New York - The U.S. was alone on Friday in a 13-1 vote for a ceasefire in the ...